We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JWEL:NASDAQJowell Global Ltd. Analysis

Data as of 2026-04-12 - not real-time

$2.43

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading just above its 20‑day moving average while the 50‑day average remains slightly lower, indicating a modest bullish bias despite a bearish MACD histogram that signals short‑term weakening momentum. RSI hovering around the neutral 50 level suggests there is no extreme overbought or oversold condition, yet the decreasing volume trend raises concerns about the sustainability of any upward moves. Price is hugging the identified support zone and remains well below the 52‑week high, while the current market price is dramatically lower than the discounted cash‑flow based fair value estimate, pointing to a severe valuation gap.
Fundamentally, the company reports negative gross, operating, and net margins, with EBITDA in the red and zero free cash flow, highlighting ongoing profitability challenges. The balance sheet shows modest cash reserves offset by a relatively high debt‑to‑equity ratio, and the book‑value per share far exceeds the market price, resulting in an ultra‑low price‑to‑book multiple. Combined with a high recent max drawdown and a volatile 30‑day price swing, the stock presents a high‑risk, deep‑value proposition that may appeal to contrarian investors seeking a turnaround play.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • bearish MACD histogram
  • decreasing trading volume
  • price testing near immediate support

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • substantial valuation discount to DCF fair value
  • low beta indicating limited market‑wide volatility
  • potential sector recovery in Chinese e‑commerce

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • deep price‑to‑book and price‑to‑sales undervaluation
  • possible turnaround as profitability improves
  • long‑term upside if Chinese consumer spending rebounds

Key Metrics & Analysis

Financial Health

Revenue Growth-11.10%
Profit Margin-4.45%
Debt/Equity11.76
P/B Ratio0.3
Op. Cash Flow$5.0M

Technical Analysis

TrendBullish
RSI51.1
Support$2.30
Resistance$2.55
MA 20$2.46
MA 50$2.35
MA 200$2.12
MACDBearish
VolumeDecreasing
Fear & Greed Index87.09

Valuation

Fair Value$23.83
GradeUndervalued
TypeValue

Risk Assessment

Beta0.33
Volatility28.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.